Eshleman, M.D., Ph.D., a professor of pathology at the Johns Hopkins University School of Medicine and head of the Network Laboratory for the HIV Avoidance Trials Network, which supported the trial. ‘This research moves the field of HIV avoidance science forward, leading us on a path toward curbing the HIV epidemic. It provides a new direction for HIV prevention research and is starting to shape public health policy.’ Eshleman says a significant next step is normally to determine whether early initiation of ARV treatment on a wider level can decrease the spread of HIV on a community or inhabitants level.. ARV drugs can prevent transmission of HIV Johns Hopkins researchers essential part of group recognized for its scientific results The locating of a team of researchers – including many users from Johns Hopkins – that HIV treatment with antiretroviral drugs can in fact prevent transmitting of the virus from an infected person to his / her uninfected partner has been named ‘Breakthrough of the entire year’ for 2011 by the journal Science.The individual human population in the trial is certainly heavily pre-treated, with 46 % having failed three prior GIST-approved TKIs. Individuals were enrolled into two cohorts predicated on the presence or absence of KIT exon 11 mutations. Primary Package mutations occur in around 85 % of patients with GIST. The most common mutation can be on exon 11 . Preclinically, ponatinib showed compelling activity against activating exon 11 mutations. ‘These preliminary data support the preclinical findings that ponatinib offers activity against the acquired mutations in Package which individuals with GIST can form following treatment with additional targeted TKIs,’ stated Michael C. Heinrich, M.D., professor of medicine and cell/developmental biology at the Knight Malignancy Institute, Oregon Health & Technology University, Portland, Oregon.